Raman Rajeshkumar

Dr. Raman Rajeshkumar

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
RARajaguru Arivuselvam
Rajaguru Arivuselvam
ADAyed A. Dera
Ayed A. Dera
SASYED PARWEEN MAZHER ALI
SYED PARWEEN MAZHER ALI
YAYasser Alraey
Yasser Alraey
ASAhmed Saif
Ahmed Saif
PRPrashantha B R
Prashantha B R
Prodigiosin pigment has high medicinal value, so exploring this compound is a top priority. This report presents a prodigiosin bioactive compound isolated from Serratia marcescens JSSCPM1, a new strain. The purification process of this compound involves the application of different chromatographic methods, including UV-visible spectroscopy, high-performance liquid chromatography (HPLC), and liquid chromatography–mass spectrometry (LC/MS). Subsequent analysis was performed using nuclear magnetic resonance (NMR) to achieve a deeper understanding of the compound’s structure. Finally, through a comprehensive review of the existing literature, the structural composition of the isolated bioactive compound was found to correspond to that of the well-known compound prodigiosin. The isolated prodigiosin compound was screened for antibacterial activity against both Gram-positive and Gram-negative bacteria. The compound inhibited the growth of Gram-negative bacterial strains compared with Gram-positive bacterial strains. It showed a maximum minimum inhibitory concentration against Escherichia coli NCIM 2065 at a 15.9 ± 0.31 μg/mL concentration. The potential binding capabilities between prodigiosin and the OmpF porin proteins (4GCS, 4GCP, and 4GCQ) were determined using in silico studies, which are generally the primary targets of different antibiotics. Comparative molecular docking analysis indicated that prodigiosin exhibits a good binding affinity toward these selected drug targets.

1 February 2020 in Process Biochemistry
Verified
Journal Article
Closed access
MSMythili Saravanan
Mythili Saravanan
PSPalanisamy Senthilkumar
Palanisamy Senthilkumar
VCVajjiram Chinnadurai
Vajjiram Chinnadurai
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
RRRaman Rajeshkumar
Raman Rajeshkumar
APArivalagan Pugazhendhi
Arivalagan Pugazhendhi

17 May 2011 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
JSJubie Selvaraj
Jubie Selvaraj
PPP. Prabitha
P. Prabitha
RRRaman Rajeshkumar
Raman Rajeshkumar
KRKalirajan Rajagopal
Kalirajan Rajagopal
RGR. Gayathri
R. Gayathri
KEK. Elango
K. Elango

13 February 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
PRPraharsh Kumar Mandadhi Rajendra
Praharsh Kumar Mandadhi Rajendra
BNBala Sai Soujith Nidamanuri
Bala Sai Soujith Nidamanuri
ASAkey Krishna Swaroop
Akey Krishna Swaroop
JKJanani Selvam Krishnamurali
Janani Selvam Krishnamurali
ABAnjali Puthusserikkunnu Balan
Anjali Puthusserikkunnu Balan
JNJawahar Natarajan
Jawahar Natarajan


25 July 2019 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
HKH. C. Kiran
H. C. Kiran
NDNAGASAMY VENKATESH DHANDAPANI
NAGASAMY VENKATESH DHANDAPANI
RRRaman Rajeshkumar
Raman Rajeshkumar
Objective: The main aim of the present investigation was to formulate and evaluate microbeads of zaltoprofen. Zaltoprofen, a BCS class II drug used in the treatment of rheumatoid arthritis. Zaltoprofen has a shorter half-life of 2.8 h, and it is administered at a dose of 80 mg thrice a day. By encapsulating the drug into microbeads, it is expected that the release of the drug would be prolonged and thereby, it reduces the frequency of administration and better patient compliance may be improved. Methods: Gellan-chitosan and calcium chloride beads of zaltoprofen were prepared employing ionotropic gelation method using different concentrations of gellan, chitosan, calcium chloride and zaltoprofen. The microbeads were evaluated for its various Physico-chemical parameters such as particle size determination, drug entrapment efficiency, infrared spectroscopy study, differential scanning calorimetry, X-ray diffraction analysis, scanning electron microscopy, in vitro drug release study and in vivo oral bioavailability studies. Results: The results suggested that the batch FG-II exhibited higher drug entrapment efficiency (72.42±0.013), a sustained drug release for a period of 24 h. The pharmacokinetic profile of the drug from microbeads exhibited an enhanced oral bioavailability (2.4 times higher than that of pure drug), lower elimination rate (1.14 times lesser for the drug in microbeads) with prolonged elimination half-life (2.561 times higher than pure zaltoprofen). Conclusion: Zaltoprofen entrapped microbeads demonstrated as a better delivery system for the sustained release of drug and also to circumvent the drawbacks associated with conventional therapy.